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Abstract
Objectives: The aim of this study was to compare the current screening methods and to evaluate confirmation tests for
phenotypic plasmidal AmpC (pAmpC) detection.
Methods: For this evaluation we used 503 Enterobacteriaceae from 18 Dutch hospitals and 21 isolates previously confirmed
to be pAmpC positive. All isolates were divided into three groups: isolates with 1) reduced susceptibility to ceftazidime and/
or cefotaxime; 2) reduced susceptibility to cefoxitin; 3) reduced susceptibility to ceftazidime and/or cefotaxime combined
with reduced susceptibility to cefoxitin. Two disk-based tests, with cloxacillin or boronic acid as inhibitor, and Etest with
cefotetan-cefotetan/cloxacillin were used for phenotypic AmpC confirmation. Finally, presence of pAmpC genes was tested
by multiplex and singleplex PCR.
Results: We identified 13 pAmpC producing Enterobacteriaceae isolates among the 503 isolates (2.6%): 9 CMY-2, 3 DHA-1
and 1 ACC-1 type in E. coli isolates. The sensitivity and specificity of reduced susceptibility to ceftazidime and/or cefotaxime
in combination with cefoxitin was 97% (33/34) and 90% (289/322) respectively. The disk-based test with cloxacillin showed
the best performance as phenotypic confirmation method for AmpC production.
Conclusions: For routine phenotypic detection of pAmpC the screening for reduced susceptibility to third generation
cephalosporins combined with reduced susceptibility to cefoxitin is recommended. Confirmation via a combination disk
diffusion test using cloxacillin is the best phenotypic option. The prevalence found is worrisome, since, due to their
plasmidal location, pAmpC genes may spread further and increase in prevalence.
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Introduction
The frequency of highly resistant gram-negative rods (HR-
GNRs) is still increasing worldwide [1]. Gram-negative rods with
resistance to carbapenems or to third generation cephalosporins
only due to ESBL-production were defined as highly resistant
isolates. Furthermore, strains resistant to two agents of the
antimicrobial groups quinolones and aminoglycosides were also
defined as highly resistant (adapted from the Dutch guideline for
preventing nosocomial transmission of highly resistant microor-
ganisms (HRMO)) [2].
Apart from ESBLs, one class of these enzymes has received
relatively little attention, namely the AmpC-type beta-lactamases.
Although these ‘‘Class C’’ beta-lactamases are often found to be
associated with the bacterial chromosome, an increasing preva-
lence of plasmid-encoded AmpC enzymes (pAmpC) has been
reported [3–5]. Traditionally, chromosomally encoded AmpC is
mainly present in group II Enterobacteriaceae (Enterobacter spp.,
Citrobacter freundii, Hafnia alvei, Providencia spp., Serratia spp.,
Morganella morganii), but pAmpC is gaining more and more
importance in group I Enterobacteriaceae (Proteus mirabilis,
Klebsiella spp., Salmonella spp., Escherichia coli, and Shigella spp.) [3].
Furthermore, carriage of plasmid-mediated AmpC is often
associated with multidrug resistance (e.g. resistance to aminogly-
cosides, quinolones and cotrimoxazole), and worryingly, isolates
with porin loss that carry pAmpC may also be resistant to
carbapenems [4,6,7]. The occurrence of pAmpC has been
investigated in several studies [6,8–10]. In a selection of clinical
Enterobacteriaceae from a national survey a high prevalence of
ampC genes among Enterobacteriaceae was found; 32 out of 181
isolates with reduced susceptibility to cefoxitin concerned pAmpC
[11]. Another study showed a high prevalence of ESBL/AmpC-
producing E. coli in birds and farmers at Dutch broiler farms [12].
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The prevalence of pAmpC carriage reported in these studies is
still low, though this is most likely an underestimation due to the
difficulties associated with routine phenotypic screening for
pAmpC. This means that molecular detection techniques are the
current ‘gold standard’ for the detection of pAmpC, although
these are more expensive and difficult to implement for routine use
[3,13]. For this reason, several previous studies have attempted to
compare and evaluate current phenotypic tests for the detection of
pAmpC [14–16]. However, most of these reports did not analyze
different screening methodologies. Therefore, the objective of this
study was to compare the current pAmpC phenotypic screening
methodologies used in the literature and to evaluate the different
confirmation methods. The methodology was further used to
assess the prevalence of pAmpC among 502 group I HR-GNRs
collected from 18 Dutch hospitals in 2007.
Materials and Methods
Bacterial isolates
Bacterial isolates were retrospectively screened using a collec-
tion of group I HR-GNR Enterobacteriaceae previously collected
during a prospective observational multicenter study in 18
hospitals in the Netherlands [17]. Gram negative rods were
defined as highly resistant (HR-GNR), according to the criteria of
the Dutch Working Party on Infection Prevention [2]. Isolates
were obtained from patients hospitalized between January 1 and
October 1, 2007 and comprised strains isolated from clinical and
screening specimens. In total 892 different HR-GNR isolates were
recovered from 786 patients.
Identification of strains, susceptibility testing and ESBL
detection was performed according to Dutch guidelines [17,18].
ESBL-encoding genes (blaCTX-M, blaSHV and blaTEM), blaOXA and
carbapenemase-encoding genes (blaKPC, blaNDM, blaOXA-48, blaIMP
and blaVIM) were detected by microarray and if necessary
confirmed by PCR and sequencing (BaseClear) at the VU
University Medical Center (VUmc) [19,20]. The authors specif-
ically focused on Enterobacterial species that are known to lack a
chromosomal AmpC gene (P. mirabilis, Klebsiella spp., Salmonella
spp.), or that are known to carry a chromosomal AmpC gene, but
produce only low levels of AmpC enzyme (E. coli and Shigella spp.).
Therefore, 503 of the 892 HR-GNR isolates from the original
study were included in the present study. The 503 highly resistant
isolates comprised E. coli (333), Klebsiella spp. (123), Proteus spp. (42),
Salmonella spp. (3) and Shigella spp. (2). Duplicate isolates from the
same patient were excluded; isolates were obtained from screening
samples (158), and from clinical samples (345); in 61 samples the
HRMO was also found in blood cultures during hospitalization.
The samples were obtained from 18 different hospitals. Finally, a
further 21 pAmpC-producing isolates, previously characterized by
PCR, were included (as positive controls) in the study collection.
Fifteen of the pAmpC control strains were obtained from the
isolate biobank available at Erasmus Medical Center, having been
collected from various non-Dutch sources over different years. The
isolates were identified as E. coli by classical biochemical methods
and confirmed to be pAmpC positive by PCR. Six isolates
(confirmed by PCR at the Erasmus MC) were isolated during a
study on community-acquired ESBL-producing Enterobacteriace-
ae at the VU University Medical Center, between August 12 and
December 13, 2011.
Screening for AmpC
Three screening strategies were evaluated: reduced susceptibil-
ity to third generation cephalosporins, reduced susceptibility to
cefoxitin, and a combination of reduced susceptibility to third
generation cephalosporins and cefoxitin [21]. Reduced suscepti-
bility to third generation cephalosporins was defined as a MIC for
cefotaxime and/or ceftazidime that was .1 mg/L, corresponding
to inhibition zone diameters for cefotaxime of #27 mm and for
ceftazidime of #22 mm (following ESBL screening protocols
defined by Dutch national guidelines) [18]. Reduced susceptibility
to cefoxitin was determined using Vitek 2 (bioMerieux, Marcy-
l’Etoile, France), and was defined as a MIC.8 mg/L according to
EUCAST guidelines [21]. If isolates were positive for pAmpC by
PCR but susceptible to cefoxitin (MIC#8 mg/L; inhibition zone
.18 mm), Vitek testing was repeated and phenotypic testing using
cefoxitin Etest (bioMe´rieux, Solna, Sweden) on Mueller Hinton
agar was performed to ensure cefoxitin sensitivity.
Confirmation of AmpC
AmpC production was confirmed phenotypically using a two
disk-based test and an Etest with boronic acid or cloxacillin as
inhibitors. The combination disk diffusion tests consisted of
cefotaxime and ceftazidime combined with boronic acid or
cloxacillin as inhibitor (Rosco, Taastrup, Denmark). A positive
test was considered when the zone of inhibition was$5 mm larger
than the zone generated without inhibitor. The Etest cefotetan/
cefotetan-cloxacillin (CN/CNI, bioMe´rieux, Marcy-l’Etoile,
France) methodology was also used to confirm AmpC production,
where either a ratio of cefotetan/cefotetan-cloxacillin $8,
deformation of the ellipse, or the presence of a phantom zone
were interpreted as positive for an AmpC producer.
Molecular pAmpC gene screening
Isolates that were suspected to be pAmpC producers by one or
more of the screening methods were further tested by multiplex
PCR. Thus, all 335 isolates with reduced susceptibility to third
generation cephalosporins and/or reduced susceptibility to cefox-
itin, were analyzed by PCR. DNA was isolated using the easyMag
system (bioMerieux, Marcy-l’Etoile, France). Plasmid-mediated
AmpC types were characterized using a variation of a standard
multiplex PCR (Erasmus MC, Rotterdam) that can identify six
family-specific pAmpC genes: blaCMY II, blaMOX, blaFOX, blaDHA,
blaACT/MIR and blaACC genes [13]. In this variation, the annealing
temperature was increased to 70uC and multiplex PCR positive
isolates were further tested using specific singleplex AmpC PCRs
under the same reaction conditions, to ensure that the PCR-
products found in the multiplex PCR positive isolates were correct.
This multiplex AmpC PCR methodology was used as the gold
standard AmpC detection methodology.
Analysis of genetic relatedness among the tested isolates in this
study was performed using amplified-fragment length polymor-
phism (AFLP) as described by Savelkoul et al. [22] Clustering and
interpretation of AFLP banding patterns were performed using
BioNumerics software, version 6.6 (Applied Maths, Sint-Martens-
Latem, Belgium).
Data analysis
Statistical analyses were performed using SPSS, version 20.0.
Sensitivity and specificity of the screening and confirmation
methods were calculated using multiplex AmpC PCR results as
the gold standard.
Results
Phenotypic detection methodologies for (plasmid-
mediated) AmpC
Of the 503 HR-GNR isolates from Dutch hospitals 335 isolates
(67%) showed reduced susceptibility to third generation cephalo-
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sporins and/or reduced susceptibility to cefoxitin. In addition
three isolates had increased MICs (.0.25 mg/L) for meropenem
(2 mg/L, 4 mg/L and 8 mg/L) and imipenem (4 mg/L, 2 mg/L
and 4 mg/L, respectively) [23]. The number of isolates for each
species included E. coli (224), Klebsiella spp. (106), Proteus spp. (4)
and Salmonella spp. (1). In total 101 screenings samples were
isolated, the remaining 234 samples were from clinical samples. Of
these, 12.9% (43/335) isolates were detected in blood cultures at a
later stage. Nearly half of the samples (42.4%, 142/335) were
obtained on the Intensive Care Unit.
Thirteen out of these 335 (3.9%) isolates were found to be
pAmpC positive using a multiplex pAmpC PCR, i.e. CMY-2 (9),
DHA-1 (3) and ACC-1 (1). Also included in the phenotypic
screening was a collection of 21 previously characterized pAmpC
positive E. coli isolates, 20 CMY-2 and one isolate with DHA-1
(data not published), generating a total of 356 isolates for
phenotypic comparison and evaluation (Table 1). Using both
screening and confirmatory phenotypic methodologies on these
356 isolates revealed three major phenotypic groups. Phenotypic
group I comprised 327 isolates that were found to be reduced
susceptible to third generation cephalosporins (regardless of
resistance to cefoxitin), with 34 (10.4%) of these isolates being
pAmpC positive by PCR. This group included all pAmpC PCR-
positive isolates. This results in a sensitivity of 100% (34/34) and a
specificity of 9% (29/322).
Phenotypic group II comprised 122 isolates with reduced
susceptibility to cefoxitin (regardless of reduced susceptibility to
third generation cephalosporins). Thirty three of these 122 (27%)
isolates were found to be pAmpC positive by PCR. An ACC-1
gene positive isolate remained undetected due to a lack of cefoxitin
resistance. This results in a sensitivity of 97% (33/34) and a
specificity of 72% (233/322).
Phenotypic group III comprised 66 isolates with reduced
susceptibility to cefoxitin combined with reduced susceptibility to
third generation cephalosporins. Thirty three of these 66 (50%)
isolates were found to be pAmpC positive by PCR, but again the
ACC-1-positive isolate remained undetected. These results gener-
ated a sensitivity of 97% (33/34), but a higher specificity of 90%
(289/322).
The performance of different AmpC confirmatory tests in
combination with different antibiotic and inhibitor combinations is
shown in Table 2. A maximum sensitivity of 94% (range 91%–
94%) was obtained for all the three screening strategies in
combination with the combination disk diffusion tests with
cloxacillin. By combining reduced susceptibility to third genera-
tion cephalosporins with reduced susceptibility to cefoxitin and in
combination with the inhibitor-based combination disk diffusion
test using cloxacillin yielded a sensitivity of 91% (31/34) with a
specificity of 96% (309/322).
The DDCT with boronic acid missed two E. coli with CMY-2.
The CN/CNI Etest did not detect three E. coli with CMY-2, one
E. coli with DHA-1 and one Klebsiella oxytoca with ACC-1.
Importantly, two E. coli isolates possessing CMY-2 type enzymes,
one coproducing CTX-M-1 and one coproducing OXA-1, were
not detected with any of the confirmation methodologies shown in
Table 2. No other isolates additionally producing ESBL were
negative in the phenotypic confirmation. All isolates with partly
negative confirmation results were fully resistant to cefotaxime,
ceftazidime and/or cefoxitin.
Molecular epidemiology
Multiplex pAmpC PCR screening revealed a prevalence of
2.6% (13/503) for pAmpC carriage among the group I
Enterobacteriaceae tested in this study. Further molecular analysis
revealed that nine of the 13 pAmpC multiplex PCR-positive
isolates, obtained in the multicenter study and isolated in five of
the 18 different hospitals between between January 1 and October
1, 2007, contained the CMY-2 gene (predominantly E. coli except
for one P. mirabilis and one Klebsiella pneumoniae). Three isolates
contained DHA-1 (all K. pneumoniae) and one isolate ACC-1 (K.
oxytoca). Two of these isolates, one E. coli with CMY-2 and one K.
pneumoniae with DHA-1, were obtained out of screening material
and the rest were clinical samples.
In three of these 13 pAmpC isolates an ESBL-encoding gene
was also detected, these ESBL genes were determined as CTX-M-
1 group (2/13) and CTX-M-9 group (1/13).
The 15 pAmpC-producers from the isolate biobank available at
Erasmus Medical Center (Erasmus MC) were obtained from
various non-Dutch sources over different years, therefore no
identical strains were expected. However, AFLP was performed on
the 6 pAmpC isolates derived from the community-acquired
ESBL-producing strains to assure that these isolates were not
identical. Furthermore, AFLP analysis of the 13 pAmpC
producers from the multicentre study revealed no epidemiological
relationship.
Discussion
Our results show that among HR-GNR in Dutch hospitals,
2.6% (13/505) pAmpC-producing isolates were found retrospec-
tively in a selected subgroup of group I Enterobacteriaceae. That
the majority of isolates possessed CMY-2 type pAmpC is in line
with molecular epidemiological results published elsewhere
[6,11,24,25].
Several reports reveal that pAmpC-producing nosocomial
isolates have become endemic in some hospitals that they can
cause outbreaks, and that they affect therapeutic choices [26–28].
Reports from Spain suggest that compared to ESBL-producing
organisms the acquisition of pAmpC-producing Enterobacteria-
ceae is still mainly hospital- or healthcare-associated [6]. The
isolates in our study were clinical isolates, but we cannot
differentiate between healthcare-associated or community-based
sources of nosocomial pAmpC infections. A rise in pAmpC
carriage and infections could in theory mirror the rapid increase in
global Enterobacterial ESBL isolates observed over the last 10
years, not least because pAmpC carriage is reportedly becoming a
serious global infectious disease health concern [5].
Table 1. AmpC production in 356 highly resistant
enterobacterial isolates.
Species
Total
collection
pAmpC
positive pAmpC type
Total 356 34
Escherichia coli 245 (68.8%) 28 (82.4%) 27 CMY-2, 1 DHA-1
Klebsiella pneumoniae 82 (23.0%) 4 (11.8%) 3 DHA-1, 1 CMY-2
Klebsiella oxytoca 24 (6.8%) 1 (2.9%) ACC-1
Proteus mirabilis 4 (1.1%) 1 (2.9%) CMY-2
Salmonella species 1 (0.3%) 0
The 356 isolates were selected based on resistance to third generation
cephalosporins (cefotaxime and/or ceftazidime) and/or cefoxitin. Reduced
susceptibility was defined as a MIC.1 mg/L corresponding to inhibition zone
diameter of#27 mm for cefotaxim, MIC.1 mg/L corresponding to inhibition zone
diameter of #22 mm for ceftazidim, MIC.8 mg/L for cefoxitin.
doi:10.1371/journal.pone.0091396.t001
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Of great concern, treatment of infections caused by pAmpC-
producing strains with cephalosporins is associated with adverse
clinical outcomes [29,30].
Recently Gude et al. evaluated different AmpC confirmatory
tests [14]. In contrast to these authors, we found not the Etest but
DDCT cloxacillin as the best test, with the best sensitivity and
specificity after the combination of screening criteria. In general
the same genes were identified, except that we detected also
blaACC-1. This difference may be due to differences in the selection
of strains. We included not only cefoxitin-resistant strains, but also
strains of group I Enterobacteriaceae that were resistant to third
generation cephalosporins alone. Therefore, cefoxitin susceptible
isolates producing pAmpC (ACC-1) could be detected. In addition
a MIC.8 mg/L was used as breakpoint for cefoxitin, as to
eliminate less resistant isolates. These more stringent MICs were
used to detect more isolates that fulfilled the screening criteria. We
used the same cefotetan/cefotetan-cloxacillin Etest, however the
other phenotypic tests were DDCT with cefotaxime/ceftazidime
combined with boronic acid or cloxacillin as inhibitor. The latter
were selected because these are commercially available, cheap and
less prone to interobserver variability (like for example a three
dimensional (3D) test or double disk approximation test).
The use of molecular testing strategies such as multiplex AmpC
PCRs are currently the gold standard for pAmpc detection. A
more convenient strategy for many institutions would be to
optimize the phenotypic screening and confirmatory methodolo-
gies that are currently available in order to maximize the
sensitivity and specificity of pAmpC detection. Results using
pAmpC phenotypic screening assays on our set of isolates showed
that a reduced susceptibility to cefotaxime and/or ceftazidime
alone generated the best sensitivity (100%, i.e. 34/34). However, a
major disadvantage of this methodology was found to be a low
specificity (9%, i.e. 29/322) of detection. This means that no false
negative results were generated using this methodology, but that
there was a relatively high frequency of false positives. The end
result is that many unnecessary confirmatory tests would have to
be performed using this methodology.
In general resistance to cefoxitin is often used as indicator for
the production of class C beta-lactamases (which include pAmpC
beta-lactamases), with most reports only investigating isolates
resistant to cephamycins [24,31]. Though cefoxitin resistance is a
sensitive test, it is not specific, mainly because a reduced
permeability of the bacterial outer membrane, as well as the
expression of some carbapenemase enzymes, may also lead to
cefoxitin resistance [32,33]. Further, hyperproduction of chromo-
somal AmpC, may lead to cephamycin resistance [3,14,34].
Another disadvantage of using cefoxitin resistance as a phenotypic
screening methodology is that ACC-1-type enzymes are suscep-
tible to cefoxitin, which means that isolates possessing these genes
will be regarded as pAmpC negative. This is an important point,
because ACC-type enzymes have been detected in several different
countries in Europe, including a large outbreak in a teaching
hospital in Garches, France [25,27,35].
From our results, we conclude that a combination of reduced
sensitivity to the third generation cephalosporins (cefotaxime and/
or ceftazidime) and reduced susceptibility to cefoxitin may
generate the best specificity (90%) for phenotypic pAmpC
screening (Table 2). A limitation however is that ACC-like
enzymes will not be detected. In combination with this screening
Table 2. Comparison of phenotypic pAmpC confirmation tests.
Phenotypic detection methods*
Total Number of
isolates positive by
pAmpC PCR
Total Number of isolates
pAmpC positive using
phenotypic methods Sensitivity (%) Specificity (%)
Phenotypic Group I:
Analysis after screening for reduced
susceptibility to third generation
cephalosporins (n = 327)
34 34 100 9
DDCT with cloxacillin 32 94 56
DDCT with boronic acid 30 88 65
Etest CN/CNI 27 79 98
Phenotypic Group II:
Analysis after screening for reduced
susceptibility to cefoxitin (n = 122)**
34 33** 97 72
DDCT with cloxacillin 31 91 93
DDCT with boronic acid 29 85 92
Etest CN/CNI 27 79 98
Phenotypic Group III:
Analysis after screening for reduced
susceptibility to all these
cephalosporins together (n = 66)**
34 33** 97 90
DDCT with cloxacillin 31 91 96
DDCT with boronic acid 29 85 95
Etest CN/CNI 27 79 98
The antibiotics used in the DDCT tests were cefotaxime and ceftazidime combined with cloxacilllin or boronic acid. Etest CN/CNI consisted of cefotetan (CN) with cefotetan-
cloxacillin (CNI).
*DDCT with cloxacillin/boronic acid and CN/CNI Etest.
**Sensitivity and specificity of these confirmation tests is performed without ACC-1 in the analysis due to susceptibility for cefoxitin.
doi:10.1371/journal.pone.0091396.t002
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strategy our results suggest that the combination disk diffusion test
with cloxacillin is the best phenotypic confirmation method.
With respect to the disk-based phenotypic confirmatory AmpC
methodologies used, it is well known that boronic acid and
cloxacillin are well-known inhibitors of AmpC [14,16,36–39].
Boronic acid is an AmpC inhibitor (both plasmidal and
chromosomal) and also an inhibitor of KPC beta-lactamases.
We found one isolate with a positive AmpC confirmation test with
boronic acid but negative results using the test with cloxacillin.
This K. pneumoniae isolate showed an increased MIC for
meropenem (2 mg/L) and was KPC positive. Of the three isolates
with MIC meropenem .0.25 mg/L one isolate (K. pneumoniae) was
KPC positive. The two other isolates (one K. pneumoniae and one E.
coli) were resistant to third generation cephalosporins and
cefoxitin, showed decreased susceptibility to ertapenem, had
negative AmpC confirmation test results and negative PCR result
for KPC. Therefore, other mechanisms could be responsible for
the resistance, e.g. porin loss and ESBLs (both isolates harboured
SHV-type ESBL and CTX-M-1, respectively) or other carbape-
nemases.
In conclusion, our data suggest that phenotypic AmpC
detection methods can be improved by combining the screening
results of susceptibility testing to third generation cephalosporins
and the susceptibility results to cefoxitin. Reduced susceptibility to
both being a good indicator for the presence of pAmpC gene
expression. However, it should be noted that the presence of ACC-
1 type AmpC will still be missed using these combined
methodologies. The presence of pAmpC can be confirmed with
the combination disk diffusion test; cefotaxime and ceftazidime
with cloxacillin showed the best results. For the future, it is
desirable to evaluate a larger collection of different enterobacterial
species with pAmpC and to perform more studies to define the
frequency of occurrence of pAmpC in comparison to 2007.
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